RxDoctor Payments Data

Leah Lemus, PA

Medical · Cleveland, OHNPI 1417498304

Payments from drug & device makers

$674in general payments, 2019–2025

Across 24 payments — averaging $28.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$378
  • Novo Nordisk$146
  • Madrigal Pharmaceuticals$55
  • Mannkind Corporation$43
  • E.r. Squibb & Sons, L.L.C.$18
  • AbbVie$13
  • plus $22 from 2 others

What the payments were for

  • Food & beverage$63194%
  • Education$436%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$674 in reported general payments places this provider in the 55th percentile of 547 medical providers in Ohio.

See all medical providers in Ohio

Medicare billing

Part B allowed, 2024
$34,101
Medicare patients
99
Services billed
657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide191$258,307
OzempicSemaglutide167$178,114
JardianceEmpagliflozin120$170,865
TrulicityDulaglutide138$160,335
FarxigaDapagliflozin Propanediol33$50,205
Fiasp FlextouchInsulin Aspart (Niacinamide)31$47,378
Humalog Kwikpen U-100Insulin Lispro97$37,901
Lantus SolostarInsulin Glargine,hum.Rec.Anlog176$31,638
JanuviaSitagliptin Phosphate17$19,595
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$17,398
Nano 2nd Gen Pen NeedlePen Needle, Diabetic136$16,453
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog52$15,694
Novolog FlexpenInsulin Aspart48$10,467
Insulin Lispro Kwikpen U-100Insulin Lispro28$6,158
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp29$5,990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$146$178,114167 claims
AbbVieSynthroid$13$54217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 547 medical providers in Ohio.

Other medical in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →